molecules of the month


oral BCL6 BTB inhibitor

promising in vitro safety + oral mouse/dog PK data

from virtual screen + SBDD

ACS Med. Chem. Lett., January 12, 2023

OICR, Toronto, CA (Janssen)

JNJ-65234637 chemical structure oral BCL6 BTB inhibitor - OICR, Toronto, CA (Janssen)
5 mins read

A protein-protein interaction inhibitor for a challenging-to-drug master transcription factor. OICR12694 is an oral protein-protein interaction inhibitor targeting the challenging-to-drug oncogenic transcription factor, B cell lymphoma 6 (BCL-6). As a master regulator of B cell differentiation in germinal centers and hence a common driver of B-cell malignancies like diffuse large B-cell lymphoma (DLBCL), BCL-6 inhibition could be beneficial for treatment of B-cell cancers and B-cell-mediated diseases. In 2015, JNJ signed a deal with Novera and the Ontario Institute for Cancer Research (OICR) to an exclusive worldwide license option for small molecules to treat blood cancers for up to $348M ($450M Canadian), in which the OICR will identify novel candidates from its drug discovery program and JNJ will be responsible for…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: